Showing results (221-230 of 395) with videos related to
Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2018
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S Davids, Michael Hallek, William Wierda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 22, 2023
Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly TrialEva Hoster, Marie-Hélène Delfau-Larue, Elizabeth Macintyre, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2012
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trialSebastian Böttcher, Matthias Ritgen, Kirsten Fischer, et al.British Journal of Haematology|June 20, 2008
Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysisTiemo Katzenberger, Dirk Kienle, Stephan Stilgenbauer, et al.Leukemia|June 24, 2025
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practicePiers Blombery, Thomas Chatzikonstantinou, Marina Gerousi, et al.Blood|August 20, 2009
Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cellsTill Seiler, Manuela Woelfle, Sophia Yancopoulos, et al.Blood|June 4, 2021
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutationsPaula Cramer, Eugen Tausch, Julia von Tresckow, et al.Cellular and Molecular Life Sciences : CMLS|September 22, 2023
Loss of ORP3 induces aneuploidy and promotes bladder cancer cell invasion through deregulated microtubule and actin dynamicsXue Wang, Junnan Liu, Anca Azoitei, et al.Leukemia & Lymphoma|August 20, 2021
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitorPhilipp Bernhard Staber, Wojciech Jurczak, Richard Greil, et al.Cancer Discovery|May 11, 2021
Discovery of Candidate DNA Methylation Cancer Driver GenesHeng Pan, Loïc Renaud, Ronan Chaligne, et al.Pageof 40